Skip to Content

James L. Murray, MD, MPH

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Currently, I am a Professor of Cancer Medicine with over 20 years experience in the treatment of breast cancer. My research interests include the immunotherapy of breast cancer, and I am chair or co-chair of several pivotal clinical trials of therapeutic and preventive vaccines in breast cancer. Having recently obtained my Masters in Public Health with a focus in cancer prevention, I am working in the Division of Epidemiology to define genetic risk factors which predispose patients to more aggressive forms of breast cancer with an emphasis on genes involved in inflammation. Most importantly, as a busy clinician I am continuously striving to offer my patients optimal breast cancer treatments in a caring and compassionate manner, with the ultimate goal of prolonging life and eventually eradicating this disease.

Education & Training

Postgraduate Training

2004-2008 Master in Public Health, Epidemiology and Disease Control, The University Of Texas School of Public Health, Houston, TX, Tommy C. Douglas, PhD
1975-1978 Fellowship, Hematology/Oncology, Ohio State University, Columbus, OH
1973-1975 Residency, Internal Medicine, University of Indiana, Indianapolis, IN
1972-1973 Rotating Internship, St. Joseph's Hospital, Denver, CO

Selected Publications

Peer-Reviewed Original Research Articles

1. Liu Y, Zhou R, Tsavachidis S, Brewster AM, Murray JL, Do K, Sahin AA, Kamrudin S, Hortobagyi GN, Taube JH, Mani SA, Batts LM, Mills GB, Bondy ML, Thompson P. Genome-wide molecular inversion probe array profiling reveals DNA copy-number imbalances associated with breast cancer bone and brain metastasis. J Clin Conol. In Press.
2. Murray JL, Thompson P, Yoo SY, Do K, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early-stage breast cancer. Breast Cancer Res and Treat. In Press.
3. Chen JQ, Xiao L, Litton JK, Zhou R, Wu Y, Sun X, Zhang H, Sahib AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Murray JL, Radvanyi LG. Prognostic value of the trichorhinopharyngeal syndrome-1 (TRPS-1) gene in early-stage breast cancer. Annals of Oncol. In Press.
4. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Freed A, Ensor J, Murray JL, Green MC, Koenig K, Lee MH, Hortobagyi GN, Yeung SC. Safety and pharmacokinetic study of exemestane in combination with Metformin and Rosiglitazone in obese postmenopausal women with hormone receptor positive metastatic breast cancer. In Press.
5. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. e-Pub 9/2012. PMID: 23053261.
6. Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lize G, Radvanyi LG. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype. Clinical Cancer Research 18(9), May 1, 2012. e-Pub 2/2012. PMCID: PMCPMC3343210.
7. Iwamoto T, Booser D, Valero V, <b>Murray JL</b>, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-34, March 1, 2012, 1/2012. PMID: 22291085.
8. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, May 1, 2012, 10/2011. e-Pub 10/2011. PMID: 22006179.
9. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavichidis S, Zhou R, Liu S, Zhang L, Mills G, Bondy M. Copy imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev and Res 4(10):1609-1616, 10/2011. e-Pub 7/2011. PMCID: PMCPMC3188338.
10. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwel D, Parker J, Mayordormo J, Tres A, Murray JL, Ibrahim NK. Phase III multicenter trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8):1092-1100, 2011. PMCID: PMCPMC3228158.
11. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clinical Cancer Research 17(21):6822-6830, 2011. PMID: 21878535.
12. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. Public Library of Science-one 6(8):e23543, 2011. PMCID: PMCPMC3155554.
13. Hortobagyi GN, young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore Jr. I. A phase II study of a fixed combination of UFT (uracil+ftorafur) and Leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10):2301-2306, 2010. PMID: 20225231.
14. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. British Journal of Cancer 103(9):1331-1334, 2010.
15. Martinez ME, Gutierrez-Millan LE, Bondy M, Daneri-Navaro A, Meza-Montenegro MM, Anduro-Corona I, Aramburo-Rubio MI, Bladeras-Pea LMA, Barragan-Ruiz JA, Brewster A, Caire-Juvera G, Castro-Cervantes JM, Zamudio MAC, Cruz G, Del Toro-Arreola A, Edgerton ME, Flores-Marquez MR. Franco-Topete RA, Garcia H, Gutierrez-Rubio SA, Hahn K, Jimenez-Perez LM, Komenaka IK, Bujanda ZAL, Lu D, Moran-Villela G, Murray JL, Nodora JN, Oceguera-Villanueva A, Martinez MAO, Michel LP, Quintero-Ramos A, Sahin A, Shim JY, Stewart M, Vazquez-Camacho G, Wertheim B, Zenuk R, Thompson P. Comparative Study of Breast Cancer in Mexican and Mexican-American Women. Health 2(9):1040-1048, 2010.
16. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke C, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein N, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Hormones and Cancer 1(1):21-33, 2010.
17. Holmes JP, Benavides L, Gates JD, Carmichael MG, Hueman TM, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26(20):3426-33, 2008. PMID: 18612158.
18. Brewster AM, Do K-A, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. The relationship between epidemiological risk factors and breast cancer recurrence. JCO 25(28):4438-44, 2008. PMID: 17785707.
19. Efferson CL, Tsuda N, Kawano K, Nistal-Villan E, Sellappan S, Yu D, Murray JL, Garcia-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol 80(1):383-94, 2006. PMID: 16352563.

Abstracts

1. Mittendorg EA, Preez SA, Hale DF, Vreeland TJ, Sears AK, Clifton GT, Ardavanis A, Shumway NM, Murray JL, Ponniah S, Papamichail M, Peoples GE. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. J Clin Oncol 30 (#109), 2012.
2. Murthy RK, Varma A, Mishra P, Hess KR, Young EJ, Murray JL, Koenig K, Green MC, Moulder SL, Melhem-Bertrandt A, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. J Clin Oncol 30 (#527), 2012.
3. Basen-Engquist K, Murray JL, Baum G, Gutierrz-Barrera A, Arun B. Randomized pilot study of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy. J Clin Oncol (#e11090), 2012.

Last updated: 8/20/2013